| Ticker: NBIX | 3050 Science Park Road | |
| Exchange: NASDAQ-National Market | San Diego, California 92121 | |
| Industry: Service | (619) 658-7600 |
| Type of Shares: | Common Shares | Filing Date: | 4/3/96 | |
| U.S. Shares: | 3,500,000 | Offer Date: | 5/23/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $8.00 - $10.00 | |
| Primary Shares: | 3,500,000 | Offer Price: | $10.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.74 | |
| Offering Amount: | $31,500,000 | Selling: | $0.42 | |
| Expenses: | $500,000 | Reallowance: | $0.10 | |
| Shares Out After: | 16,582,548 |
| Manager | Tier | Phone |
| Robertson, Stephens & Company | Lead Manager | (415) 989-8500 |
| Alex. Brown & Sons Incorporated | Co-manager | (410) 727-1700 |
| Montgomery Securities | Co-manager | 4156272220 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $6.11 | $2.16 | $2.75 | Assets: | $28.08 |
| Net Income: | -$3.35 | $0.03 | $0.41 | Liabilities: | $3.86 |
| EPS: | -$0.27 | $0.00 | $0.03 | Equity: | $24.22 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a neuroimmunology company focused on the discovery and development of novel therapeutics to treat diseases and disorders of the central nervous and immune systems. The company's neuroscience and immunology disciplines provide a unique biological understanding of the molecular interactions between the central nervous, immune and endocrine systems leading to therapeutic opportunities for diseases and disorders such as anxiety, depression, Alzheimer's disease, obesity and multiple sclerosis. Neurocrine is leveraging its resources through strategic alliances and novel financing mechanisms to build its internal product development and commercialization capabilities. To date, Neurocrine has entered into strategic alliances with Janssen Pharmaceutica, N.V., a subsidiary of Johnson & Johnson, focused on the treatment of anxiety, depression and substance abuse, and Ciba-Geigy Limited, for the treatment of multiple sclerosis. In conjunction with a number of institutional investors, the company has also established a research and development subsidiary in Canada., Neuroscience Pharma Inc., to develop additional compounds for the treatment of alzheimer's disease and other neurodegenerative diseases and disorders. |
| Use of Proceeds |
| The proceeds from the offering will be used for research and development. capital expenditures, the acquisition of technology rights and for general corporate purposes, including working capital. |
©1996 IPO Data Systems, Inc. - All rights reserved.